The FDA has approved mirdametinib, the first oral drug for treating plexiform neurofibromas in patients with neurofibromatosis type 1 (NF1). The drug is indicated for adults and children aged 2 years and older who have symptomatic or inoperable tumours. This decision opens up new opportunities to improve the quality of life for patients with this complex disease.
